Trends in high intensity statin use among secondary prevention patients 76 years and older

被引:0
作者
Wood, Michele [1 ]
Delate, Thomas [1 ]
Stadler, Sheila L. [1 ]
Denham, Anne M. [1 ]
Ruppe, Leslie K. [1 ]
Hornak, Roseanne [1 ]
Olson, Kari L. [1 ]
机构
[1] Kaiser Permanente Colorado, Pharm Dept, Aurora, CO 80014 USA
来源
PHARMACY PRACTICE-GRANADA | 2019年 / 17卷 / 02期
关键词
Hydroxymethylglutaryl-CoA Reductase Inhibitors; Coronary Artery Disease; Delivery of Health Care; Integrated; Health Services for the Aged; Aged; Prescription Drugs; Comparative Effectiveness Research; Drug Utilization; Retrospective Studies; United States; RISK; THERAPY; ASSOCIATION; MORTALITY; DISEASE;
D O I
10.18549/PharmPract.2019.2.1402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: High intensity statin therapy (HIST) is the gold standard therapy for decreasing the risk of recurrent atherosclerotic cardiovascular disease (ASCVD); however, little is known about the use of HIST in older adults with ASCVD. Objectives: The aim of this cross-sequential study was to determine trends in statin intensity in older adults over a 10-year timeframe. Methods: The study was conducted in an integrated healthcare delivery system. Patients were 76 years or older with validated coronary ASCVD. Data were collected from administrative databases. Statin intensity level was assessed in eligible patients on January 1st and July 1st from January 1, 2007 to December 31, 2016. Results: Overall, a total of 5,453 patients were included with 2,119 (38.9%) and 3,334 (61.1%) categorized as HIST and Non-HIST, respectively. Included patients had a mean age of 79.8 years and were primarily male and white and had a cardiac intervention. The rate of HIST use increased from 14.5% to 41.3% over the study period (p<0.001 for trend). Conversely, the rates of moderate and low intensity statin use decreased from 61.8% and 9.8% to 41.2% and 4.8%, respectively (both p<0.001 for trend). Similar trends were identified for females and males. Conclusions: The percentage of patients with ASCVD 76 years and older who received HIST substantially increased from 2007 to 2016. This trend was identified in both females and males. Future comparative effectiveness research should be conducted in this patient population to examine cardiac-related outcomes with HIST and Non-HIST use.
引用
收藏
页数:8
相关论文
共 19 条
  • [1] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [2] A CHRONIC DISEASE SCORE WITH EMPIRICALLY DERIVED WEIGHTS
    CLARK, DO
    VONKORFF, M
    SAUNDERS, K
    BALUCH, WM
    SIMON, GE
    [J]. MEDICAL CARE, 1995, 33 (08) : 783 - 795
  • [3] 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    Goff, David C., Jr.
    Lloyd-Jones, Donald M.
    Bennett, Glen
    Coady, Sean
    D'Agostino, Ralph B., Sr.
    Gibbons, Raymond
    Greenland, Philip
    Lackland, Daniel T.
    Levy, Daniel
    O'Donnell, Christopher J.
    Robinson, Jennifer G.
    Schwartz, J. Sanford
    Shero, Susan T.
    Smith, Sidney C., Jr.
    Sorlie, Paul
    Stone, Neil J.
    Wilson, Peter W. F.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (25) : 2935 - 2959
  • [4] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Grundy, SM
    Cleeman, JI
    Merz, CNB
    Brewer, HB
    Clark, LT
    Hunninghake, DB
    Pasternak, RC
    Smith, SC
    Stone, NJ
    [J]. CIRCULATION, 2004, 110 (02) : 227 - 239
  • [5] Lipid-lowering therapy with statins in high-risk elderly patients - The treatment-risk paradox
    Ko, DT
    Mamdani, M
    Alter, DA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (15): : 1864 - 1870
  • [6] Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service
    Lamprecht, Donald G., Jr.
    Shaw, Paul B.
    King, Jordan B.
    Hogan, Keri N.
    Olson, Kari L.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 999 - 1007
  • [7] Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease
    Merenich, John A.
    Olson, Kari L.
    Delate, Thomas
    Rasmussen, Jon
    Helling, Dennis K.
    Ward, David G.
    [J]. PHARMACOTHERAPY, 2007, 27 (10): : 1370 - 1378
  • [8] Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
  • [9] Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults
    Musich, Shirley
    Wang, Shaohung S.
    Schwebke, Kay
    Slindee, Luke
    Waters, Evonne
    Yeh, Charlotte S.
    [J]. POPULATION HEALTH MANAGEMENT, 2019, 22 (01) : 74 - 82
  • [10] Statin Use and Adverse Effects Among Adults &gt;75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
    Nanna, Michael G.
    Navar, Ann Marie
    Wang, Tracy Y.
    Mi, Xiaojuan
    Virani, Salim S.
    Louie, Michael J.
    Lee, L. Veronica
    Goldberg, Anne C.
    Roger, Veronique L.
    Robinson, Jennifer
    Peterson, Eric D.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (10):